952511-48-7

Basic information

• Product Name: 952511-48-7 5-broMo-4-Methyl-1H-benzo[d]iMidazole
• Synonyms: 952511-48-7 5-broMo-4-Methyl-1H-benzo[d]iMidazole;5-broMo-4-Methyl-1H-benzo[d]iMidazole;6-bromo-7-methyl-1H-benzo[d]imidazole
• CAS NO: 952511-48-7
• Molecular Formula: C₈H₇BrN₂
• Molecular Weight: 211.05858
• Mol File: 952511-48-7.mol

Chemical Properties

• Boiling Point: 418.3±25.0 °C(Predicted)
• Appearance: /
• Density: 1.654±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.60±0.30(Predicted)
• CAS DataBase Reference: 952511-48-7 5-broMo-4-Methyl-1H-benzo[d]iMidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 952511-48-7 5-broMo-4-Methyl-1H-benzo[d]iMidazole(952511-48-7)
• EPA Substance Registry System: 952511-48-7 5-broMo-4-Methyl-1H-benzo[d]iMidazole(952511-48-7)

Safety Data

• Hazardous Substances Data: 952511-48-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
952511-48-7, 5-bromo-4-methyl-1H-benzo[d]imidazole, is utilized as a key building block in organic synthesis for the creation of a range of biologically active compounds. Its unique structure and reactivity contribute to the development of new organic molecules with potential applications in various fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 5-bromo-4-methyl-1H-benzo[d]imidazole is employed as a crucial component in the research and development of new drugs. Its potential pharmacological properties make it a promising candidate for the synthesis of pharmaceuticals with novel therapeutic effects.
Used in the Production of Pharmaceuticals:
952511-48-7
5-broMo-4-Methyl-1H-benzo[d]iMidazole is also used in the manufacturing process of various pharmaceuticals. Its presence in the synthesis of drugs can enhance their efficacy and contribute to the development of innovative treatments for a wide range of medical conditions.
Used in the Production of Fine Chemicals:
Beyond pharmaceuticals, 5-bromo-4-methyl-1H-benzo[d]imidazole is utilized in the production of fine chemicals. Its versatility and reactivity make it suitable for the synthesis of high-quality specialty chemicals used in various industries, including agriculture, fragrances, and more.
Used in Biological and Medicinal Applications:
As a bromo-substituted benzimidazole, 952511-48-7 has the potential for use in biological and medicinal applications. Researchers in the pharmaceutical and chemical industries may find 952511-48-7 5-broMo-4-Methyl-1H-benzo[d]iMidazole of interest for its potential to contribute to the development of new therapies and diagnostic tools.

Upstream product

• 64-18-6 formic acid 
• 290353-57-0 1-bromo-2-methyl-3,4-dinitrobenzene 
• 55289-35-5 2-bromo-6-nitrotoluene 
• 952511-74-9 4-bromo-3-methyl-1,2-benzenediamine 
• 122-51-0 orthoformic acid triethyl ester 

Downstream Products

• 952511-70-5 7-methyl-1H-benzimidazole-6-carbonitrile 
• 1008361-60-1 5-Bromo-4-methyl-1-(triphenylmethyl)-1H-benzimidazole 
• 952511-70-5 4-methyl-1H-benzo[d]imidazole-5-carbonitrile 

Relevant articles and documents

Thermodynamic parameters for binding of some halogenated inhibitors of human protein kinase CK2

The interaction of human CK2α with a series of tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) analogs, in which one of the bromine atoms proximal to the triazole/imidazole ring is replaced by a methyl group, was studied by biochemical (IC50) and biophysical methods (thermal stability of protein-ligand complex monitored by DSC and fluorescence). Two newly synthesized tri-bromo derivatives display inhibitory activity comparable to that of the reference compounds, TBBt and TBBz, respectively. DSC analysis of the stability of protein-ligand complexes shows that the heat of ligand binding (Hbind) is driven by intermolecular electrostatic interactions involving the triazole/imidazole ring, as indicated by a strong correlation between Hbind and ligand pKa. Screening, based on fluorescence-monitored thermal unfolding of protein-ligand complexes, gave comparable results, clearly identifying ligands that most strongly bind to the protein. Overall results, additionally supported by molecular modeling, confirm that a balance of hydrophobic and electrostatic interactions contribute predominantly, relative to possible intermolecular halogen bonding, in binding of the ligands to the CK2α ATP-binding site.

SERINE/THREONINE PAK1 INHIBITORS

Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor

Bicyclic heteroaryl-substituted imidazole compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H4 receptor activity

HETERO COMPOUND

[Problems] To provide a useful compound as an active ingredient for a preventing and/or treating agent for rejection in the transplantation of an organ, bone marrow, or a tissue, an autoimmune disease, or the like, which has an excellent S1P1 a